THC Therapeutics, Inc. has announced the acquisition of The Headquarters Group, Inc., consolidating its position in the legal cannabis industry. The transaction, valued at approximately $11 million, was completed through the issuance of 11,007 thousand shares of Series D Preferred stock. This strategic move unites THC Therapeutics with The Headquarters Group, a company with over 60 years of combined experience in genetics, cultivation, extraction, and distribution, as well as specialty real estate and nutrients for cannabis growers. The acquisition includes companies with a combined revenue of $4.8 million and is intended to maximize efficiencies and generate significant revenue through a fully integrated vertical cannabis platform.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。